Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Clinical Outlook
  • Published:

Finding the positive in triple-negative breast cancer

Nature Cancer volume 2, pages 476–478 (2021)Cite this article

Subjects

The treatment of triple-negative breast cancer remains chemotherapy based and lacks targeted drugs. However, immunotherapy combinations have shown promising activity, targeted chemotherapy options via antibody–drug conjugates are in the clinic, and molecular means of identifying targetable subsets are on the horizon. This Clinical Outlook discusses current and future possibilities for treating triple-negative breast cancer.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Fig. 1: Treatment for mTNBC in the current state and in a potential future state.

References

  1. Hoadley, K. A. et al. Cell 173, 291–304.e296 (2018).

    Article  CAS  Google Scholar 

  2. Ring, B. Z. et al. BMC Cancer 16, 143 (2016).

    Article  Google Scholar 

  3. Burstein, M. D. et al. Clin. Cancer Res. 21, 1688–1698 (2015).

    Article  CAS  Google Scholar 

  4. Siegel, M. B. et al. J. Clin. Invest. 128, 1371–1383 (2018).

    Article  Google Scholar 

  5. Tutt, A. et al. Nat. Med. 24, 628–637 (2018).

    Article  CAS  Google Scholar 

  6. Bardia, A. et al. N. Engl. J. Med. 380, 741–751 (2019).

    Article  CAS  Google Scholar 

  7. Tung, N. M. et al. J. Clin. Oncol. 38, 4274–4282 (2020).

    Article  CAS  Google Scholar 

  8. Schmid, P. et al. N. Engl. J. Med. 379, 2108–2121 (2018).

    Article  CAS  Google Scholar 

  9. Cortes, J. et al. Lancet 396, 1817–1828 (2020).

    Article  Google Scholar 

  10. Carey, L. A. et al. J. Clin. Oncol. 30, 2615–2623 (2012).

    Article  CAS  Google Scholar 

  11. Zawistowski, J. S. et al. Cancer Discov. 7, 302–321 (2017).

    Article  CAS  Google Scholar 

  12. Voorwerk, L. et al. Nat. Med. 25, 920–928 (2019).

    Article  CAS  Google Scholar 

  13. Mittendorf, E. A. et al. Lancet 396, 1090–1100 (2020).

    Article  CAS  Google Scholar 

  14. Schmid, P. et al. N. Engl. J. Med. 382, 810–821 (2020).

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. University of North Carolina, Chapel Hill, NC, USA

    Lisa A. Carey

Authors
  1. Lisa A. Carey
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Lisa A. Carey.

Ethics declarations

Competing interests

The author declares no competing interests.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Carey, L.A. Finding the positive in triple-negative breast cancer. Nat Cancer 2, 476–478 (2021). https://doi.org/10.1038/s43018-021-00211-x

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s43018-021-00211-x

This article is cited by

Search

Advanced search

Quick links

Nature Briefing: Cancer

Sign up for the Nature Briefing: Cancer newsletter — what matters in cancer research, free to your inbox weekly.

Get what matters in cancer research, free to your inbox weekly. Sign up for Nature Briefing: Cancer